Skip to content

Technical Performance of a New Cardiac Technology IQ-SPECT Applied to SCINTI-CT Myocardial Imaging With 99mTc-Sestamibi in Coronary Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02524600
Acronym
IQSCINTIMYOC
Enrollment
103
Registered
2015-08-17
Start date
2012-01-31
Completion date
Unknown
Last updated
2015-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

Cardiological examination is one of the major directions in nuclear medicine for detection of myocardial ischemia in patients with suspected coronary artery disease. In Caen, they constitute 20% of the activity of nuclear medicine. It is evaluating a new versatile innovative technology (IQ-SPECT) for performing rapid nuclear cardiological examinations (4 minutes) and quality on a SCINTI-CT camera for correcting the mitigation. This technical solution IQ-SPECT was made available to the nuclear medicine department in August 2011. To date, apart from the work on heart ghosts and one publication in abstract form in 2009, no other study have been published. The goal of the study is to study the technical performance of the innovative technology IQ-SPECT during a SCINTI-CT imaging in patients suspected of coronary disease .

Interventions

DEVICEmyocardial IQ-SPECT imaging applied to scintigraphic imaging
DEVICEscintigraphic imaging

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age over 18 years (except major patients under guardianship) * free and informed consent signed * written and spoken French * beneficiaries of the social security system * coronary insufficiency detection needed for patients with signs or symptoms suggestive of coronary insufficiency; or in symptomatic patients, but with a high risk of coronary heart disease: diabetes and / or with multiple cardiovascular risk factors and / or having a peripheral vascular disease

Exclusion criteria

* Patients with a recent history (\<21 days) acute coronary failure (myocardial infarction, unstable angina); * Patients with an irregular heartbeat, because of the impossibility of achieving a good quality ECG synchronization (atrial fibrillation, ventricular extra-systole or supraventricular over 25% of cardiac cycles); * Patients with a pacemaker with a permanent electro-drive at rest; * Patients with non-ischemic heart disease: primitive dilated cardiomyopathy, severe hypertrophic cardiomyopathy, severe valvular cardiomyopathy (aortic stenosis, aortic or mitral leakage grade\> 2), congenital heart disease; * Patients with severe extra-cardiac disease may interfere with treatment decisions (cancer, severe hepatic or renal impairment); * Major patients under guardianship; * Pregnant or lactating women; * Women in age and condition of childbearing; * Patients unable to understand the purpose of the study. Cons-indications to physical stress test: * Uncontrolled heart failure, * Pulmonary embolism, phlebitis evolution, * Myocarditis, pericarditis, endocarditis evolving * Physical disability, * Thrombus * Asthma * contra-indication for exercise testing as dipyridamole: * Severe Asthma

Design outcomes

Primary

MeasureTime frameDescription
Myocardial perfusion bindingbaseline* 0 = normal fixing ≥70% * 1 = slightly reduced mounting 50-69% * 2 = moderately less attachment 30-49% * 3 = severely diminished attachment 10-20% * 4 = no binding \<10%

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026